Skip to main content
SpringerLink
Log in

Drug-Induced Cholangiopathies

  • Chapter
  • First Online:
Diseases of the Liver and Biliary Tree

  • 582 Accesses

Abstract

Since it plays a central role in the metabolism of xenobiotics, including drugs, the liver is one of the main targets of drug toxicity, often due to active metabolites. Liver toxicity is a challenging issue and a frequent cause of failure during drug development. In particular, drug-induced bile duct injury is a side effect of several drugs and dietary supplements, that can be either easy to manage and characterized by a good outcome, or mostly unpredictable, difficult to treat, and even potentially fatal. In fact, drug-induced bile duct injury could display a wide range of pathological features, ranging from asymptomatic patients that exhibit only isolated elevations in biochemical markers and mild bile duct disorder or “ductopenia,” to progressive forms of vanishing bile duct syndrome. In the majority of patients, drug-induced bile duct injury affects the biliary epithelium of interlobular ducts, as happens in other cholangiopathies, such as primary biliary cholangitis or small duct primary sclerosing cholangitis. A precise characterization of the molecular pathophysiological mechanisms of drug-induced cholangiopathies, and the gene profiling of susceptible patients may help the prediction of biliary drug-induced liver injury still during the preclinical phase of drug development, leading to the identification of subsets of patients who are at risk of this adverse drug reaction, which remains difficult to treat and with an uncertain outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Padda MS, Sanchez M, Akhtar AJ, Boyer JL. Drug-induced cholestasis. Hepatology. 2011;53(4):1377–87.

    Article  CAS  PubMed  Google Scholar 

  2. Bohan A, Boyer JL. Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Semin Liver Dis. 2002;22(2):123–36.

    Article  CAS  PubMed  Google Scholar 

  3. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42(2):481–9.

    Article  PubMed  CAS  Google Scholar 

  4. Reau NS, Jensen DM. Vanishing bile duct syndrome. Clin Liver Dis. 2008;12(1):203–17, x.

    Article  PubMed  Google Scholar 

  5. Bonkovsky HL, Kleiner DE, Gu J, Odin JA, Russo MW, Navarro VM, et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology. 2017;65(4):1267–77.

    Article  CAS  PubMed  Google Scholar 

  6. Lazaridis KN, LaRusso NF. The cholangiopathies. Mayo Clin Proc. 2015;90(6):791–800.

    Article  CAS  PubMed  Google Scholar 

  7. O’Hara SP, Tabibian JH, Splinter PL, LaRusso NF. The dynamic biliary epithelia: molecules, pathways, and disease. J Hepatol. 2013;58(3):575–82.

    Article  PubMed  Google Scholar 

  8. Desmet VJ. Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol. 1997;26(Suppl 1):31–5.

    Article  CAS  PubMed  Google Scholar 

  9. Björnsson ES, Jonasson JG. Idiosyncratic drug-induced liver injury associated with bile duct loss and vanishing bile duct syndrome: rare but has severe consequences. Hepatology. 2017;65(4):1091–3.

    Article  PubMed  Google Scholar 

  10. Degott C, Feldmann G, Larrey D, Durand-Schneider A-M, Grange D, Machayekhi J-P, et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology. 1992;15(2):244–51.

    Article  CAS  PubMed  Google Scholar 

  11. Visentin M, Lenggenhager D, Gai Z, Kullak-Ublick GA. Drug-induced bile duct injury. Biochim Biophys Acta Mol basis Dis. 2018;1864(4 Pt B):1498–506.

    Article  CAS  PubMed  Google Scholar 

  12. Geubel AP, Sempoux CL. Drug and toxin-induced bile duct disorders. J Gastroenterol Hepatol. 2000;15(11):1232–8.

    CAS  PubMed  Google Scholar 

  13. Greca RD, Cunha-Silva M, Costa LBE, Costa JGF, Mazo DFC, Sevá-Pereira T, et al. Vanishing bile duct syndrome related to DILI and Hodgkin lymphoma overlap: a rare and severe case. Ann Hepatol. 2020;19(1):107–12.

    Article  PubMed  Google Scholar 

  14. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf. 2007;6(6):673–84.

    Article  CAS  PubMed  Google Scholar 

  15. Sundaram V, Björnsson ES. Drug-induced cholestasis. Hepatol Commun. 2017;1(8):726–35.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Hashim A, Barnabas A, Miquel R, Agarwal K. Successful liver transplantation for drug-induced vanishing bile duct syndrome. BMJ Case Rep. 2020;13(1):e233052.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Levine C, Trivedi A, Thung SN, Perumalswami PV. Severe ductopenia and cholestasis from levofloxacin drug-induced liver injury: a case report and review. Semin Liver Dis. 2014;34(2):246–51.

    Article  CAS  PubMed  Google Scholar 

  18. Björnsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports. Hepatology. 2016;63(2):590–603.

    Article  PubMed  Google Scholar 

  19. Ko YJ, Karanicolas PJ. Hepatic arterial infusion pump chemotherapy for colorectal liver metastases: an old technology in a new era. Curr Oncol. 2014;21(1):e116–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Daly JM, Kemeny N, Oderman P, Botet J. Long-term hepatic arterial infusion chemotherapy. Anatomic considerations, operative technique, and treatment morbidity. Arch Surg. 1984;119(8):936–41.

    Article  CAS  PubMed  Google Scholar 

  21. Ito K, Ito H, Kemeny NE, Gonen M, Allen PJ, Paty PB, et al. Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors. Ann Surg Oncol. 2012;19(5):1609–17.

    Article  PubMed  Google Scholar 

  22. Kemeny N, Seiter K, Niedzwiecki D, Chapman D, Sigurdson E, Cohen A, et al. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer. 1992;69(2):327–34.

    Article  CAS  PubMed  Google Scholar 

  23. Jin S, Shi X-J, Sun X-D, Wang S-Y, Wang G-Y. Sclerosing cholangitis secondary to bleomycin-iodinated embolization for liver hemangioma. World J Gastroenterol. 2014;20(46):17680–5.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Gudnason HO, Björnsson HK, Gardarsdottir M, Thorisson HM, Olafsson S, Bergmann OM, et al. Secondary sclerosing cholangitis in patients with drug-induced liver injury. Dig Liver Dis. 2015;47(6):502–7.

    Article  PubMed  Google Scholar 

  25. Sahin M, Eryilmaz R, Bulbuloglu E. The effect of scolicidal agents on liver and biliary tree (experimental study). J Investig Surg. 2004;17(6):323–6.

    Article  Google Scholar 

  26. Seto W-K, Ng M, Chan P, Ng IO-L, Cheung SC-W, Hung IF-N, et al. Ketamine-induced cholangiopathy: a case report. Am J Gastroenterol. 2011;106(5):1004–5.

    Article  PubMed  Google Scholar 

  27. Lo RSC, Krishnamoorthy R, Freeman JG, Austin AS. Cholestasis and biliary dilatation associated with chronic ketamine abuse: a case series. Singap Med J. 2011;52(3):e52–5.

    CAS  Google Scholar 

  28. Wong SW, Lee KF, Wong J, Ng WWC, Cheung YS, Lai PBS. Dilated common bile ducts mimicking choledochal cysts in ketamine abusers. Hong Kong Med J. 2009;15(1):53–6.

    CAS  PubMed  Google Scholar 

  29. Turkish A, Luo JJ, Lefkowitch JH. Ketamine abuse, biliary tract disease, and secondary sclerosing cholangitis. Hepatology. 2013;58(2):825–7.

    Article  PubMed  Google Scholar 

  30. Nayudu SK, Badipatla S, Niazi M, Balar B. Cholestatic hepatitis with small duct injury associated with celecoxib. Case Rep Med. 2013;2013:e315479. https://www.hindawi.com/journals/crim/2013/315479/. Accessed 3 Apr 2020.

    Article  Google Scholar 

  31. Androgenic steroids. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548931/. Accessed 27 Apr 2020.

  32. Carmustine. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548307/. Accessed 27 Apr 2020.

  33. Rosenberg WM, Ryley NG, Trowell JM, McGee JO, Chapman RW. Dextropropoxyphene induced hepatotoxicity: a report of nine cases. J Hepatol. 1993;19(3):470–4.

    Article  CAS  PubMed  Google Scholar 

  34. Gold preparations. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548786/. Accessed 27 Apr 2020.

  35. Zimmerman HJ, Lewis JH. Drug-induced cholestasis. Med Toxicol. 1987;2(2):112–60.

    Article  CAS  PubMed  Google Scholar 

  36. Bataller R, Bragulat E, Nogué S, Görbig MN, Bruguera M, Rodés J. Prolonged cholestasis after acute paraquat poisoning through skin absorption. Am J Gastroenterol. 2000;95(5):1340–3.

    Article  CAS  PubMed  Google Scholar 

  37. Masubuchi Y. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metab Pharmacokinet. 2006;21(5):347–56.

    Article  CAS  PubMed  Google Scholar 

  38. Patel H, Sonawane Y, Jagtap R, Dhangar K, Thapliyal N, Surana S, et al. Structural insight of glitazone for hepato-toxicity: resolving mystery by PASS. Bioorg Med Chem Lett. 2015;25(9):1938–46.

    Article  CAS  PubMed  Google Scholar 

  39. Trak-Smayra V, Cazals-Hatem D, Asselah T, Duchatelle V, Degott C. Prolonged cholestasis and ductopenia associated with tenoxicam. J Hepatol. 2003;39(1):125–8.

    Article  CAS  PubMed  Google Scholar 

  40. Mullish BH, Fofaria RK, Smith BC, Lloyd K, Lloyd J, Goldin RD, et al. Severe cholestatic jaundice after a single administration of ajmaline; a case report and review of the literature. BMC Gastroenterol. 2014;14:60.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Amitriptyline. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548410/. Accessed 27 Apr 2020.

  42. Ortega-Alonso A, Andrade RJ. Chronic liver injury induced by drugs and toxins. J Dig Dis. 2018;19(9):514–21.

    Article  PubMed  Google Scholar 

  43. Amiodarone. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548109/. Accessed 27 Apr 2020.

  44. Hautekeete ML, Brenard R, Horsmans Y, Henrion J, Verbist L, Derue G, et al. Liver injury related to amoxycillin-clavulanic acid: interlobular bile-duct lesions and extrahepatic manifestations. J Hepatol. 1995;22(1):71–7.

    Article  CAS  PubMed  Google Scholar 

  45. Smith LA, Ignacio JRA, Winesett MP, Kaiser GC, Lacson AG, Gilbert-Barness E, et al. Vanishing bile duct syndrome: amoxicillin-clavulanic acid associated intra-hepatic cholestasis responsive to ursodeoxycholic acid. J Pediatr Gastroenterol Nutr. 2005;41(4):469–73.

    Article  CAS  PubMed  Google Scholar 

  46. Richardet JP, Mallat A, Zafrani ES, Blazquez M, Bognel JC, Campillo B. Prolonged cholestasis with ductopenia after administration of amoxicillin/clavulanic acid. Dig Dis Sci. 1999;44(10):1997–2000.

    Article  CAS  PubMed  Google Scholar 

  47. O’Donohue J, Oien K, Donaldson P, Underhill J, Clare M, MacSween R, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut. 2000;47(5):717–20.

    Article  PubMed  PubMed Central  Google Scholar 

  48. deLemos AS, Ghabril M, Rockey DC, Gu J, Barnhart HX, Fontana RJ, et al. Amoxicillin–clavulanate-induced liver injury. Dig Dis Sci. 2016;61(8):2406–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Hautekeete ML, Horsmans Y, Van Waeyenberge C, Demanet C, Henrion J, Verbist L, et al. HLA association of amoxicillin-clavulanate--induced hepatitis. Gastroenterology. 1999;117(5):1181–6.

    Article  CAS  PubMed  Google Scholar 

  50. Cavanzo FJ, Garcia CF, Botero RC. Chronic cholestasis, paucity of bile ducts, red cell aplasia, and the Stevens-Johnson syndrome. An ampicillin-associated case. Gastroenterology. 1990;99(3):854–6.

    Article  CAS  PubMed  Google Scholar 

  51. Ampicillin. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK547894/. Accessed 27 Apr 2020.

  52. Dev HY, et al. Reversible cholestasis with bile duct injury following azathioprine therapy. A case report. Liver. 1991;11:89. https://www.ncbi.nlm.nih.gov/pubmed/2051906. Accessed 27 Apr 2020.

    Google Scholar 

  53. Azathioprine. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548332/. Accessed 27 Apr 2020.

  54. Pagliaro L, Campesi G, Aguglia F. Barbiturate jaundice. Report of a case due to a barbital-containing drug, with positive rechallenge to phenobarbital. Gastroenterology. 1969;56(5):938–43.

    Article  CAS  PubMed  Google Scholar 

  55. Babbs C, Warnes TW. Primary biliary cirrhosis after benoxaprofen. Br Med J (Clin Res Ed). 1986;293(6541):241.

    Article  CAS  Google Scholar 

  56. Nonsteroidal antiinflammatory drugs (NSAIDs). In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548614/. Accessed 27 Apr 2020.

  57. Ramos AMO, Gayotto LCC, Clemente CM, Mello ES, Luz KG, Freitas ML. Reversible vanishing bile duct syndrome induced by carbamazepine. Eur J Gastroenterol Hepatol. 2002;14(9):1019–22.

    Article  CAS  PubMed  Google Scholar 

  58. Forbes GM, Jeffrey GP, Shilkin KB, Reed WD. Carbamazepine hepatotoxicity: another cause of the vanishing bile duct syndrome. Gastroenterology. 1992;102(4 Pt 1):1385–8.

    Article  CAS  PubMed  Google Scholar 

  59. de Galoscy C, Horsmans Y, Rahier J, Geubel AP. Vanishing bile duct syndrome occurring after carbamazepine administration: a second case report. J Clin Gastroenterol. 1994;19(3):269–71.

    Article  PubMed  Google Scholar 

  60. Levy M, Goodman MW, Van Dyne BJ, Sumner HW. Granulomatous hepatitis secondary to carbamazepine. Ann Intern Med. 1981;95(1):64–5.

    Article  CAS  PubMed  Google Scholar 

  61. Husebye KO. Jaundice with persisting pericholangiolitic inflammation in a patient treated with chlorothiazide. Dig Dis Sci. 1964;9(6):439–46.

    Article  CAS  Google Scholar 

  62. Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, et al. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology. 1994;20(6):1437–41.

    Article  CAS  PubMed  Google Scholar 

  63. Chlorpromazine. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548793/. Accessed 27 Apr 2020.

  64. Ishak KG, Irey NS. Hepatic injury associated with the phenothiazines. Clinicopathologic and follow-up study of 36 patients. Arch Pathol. 1972;93(4):283–304.

    CAS  PubMed  Google Scholar 

  65. Geubel AP, Nakad A, Rahier J, Dive C. Prolonged cholestasis and disappearance of interlobular bile ducts following chlorpropamide and erythromycin ethylsuccinate. Case of drug interaction? Liver. 1988;8(6):350–3.

    Article  CAS  PubMed  Google Scholar 

  66. Cimetidine. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548130/. Accessed 27 Apr 2020.

  67. Ciprofloxacin. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548066/. Accessed 27 Apr 2020.

  68. Clindamycin. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548292/. Accessed 27 Apr 2020.

  69. Larrey D, Geneve J, Pessayre D, Machayekhi JP, Degott C, Benhamou JP. Prolonged cholestasis after cyproheptadine-induced acute hepatitis. J Clin Gastroenterol. 1987;9(1):102–4.

    Article  CAS  PubMed  Google Scholar 

  70. Cyproheptadine. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548422/. Accessed 27 Apr 2020.

  71. Penicillamine. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548246/. Accessed 27 Apr 2020.

  72. Kawasaki Y, Matsubara K, Hashimoto K, Tanigawa K, Kage M, Iwata A, et al. Nonsteroidal anti-inflammatory drug-induced vanishing bile duct syndrome treated with plasmapheresis. J Pediatr Gastroenterol Nutr. 2013;57(5):e30–1.

    Article  PubMed  Google Scholar 

  73. Erythromycin. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK547881/. Accessed 27 Apr 2020.

  74. Lieberman DA, Keeffe EB, Stenzel P. Severe and prolonged oral contraceptive jaundice. J Clin Gastroenterol. 1984;6(2):145–8.

    Article  CAS  PubMed  Google Scholar 

  75. Estrogens and oral contraceptives. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548539/. Accessed 27 Apr 2020.

  76. Fenofibrate. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548607/. Accessed 27 Apr 2020.

  77. Davies MH, Harrison RF, Elias E, Hübscher SG. Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis. J Hepatol. 1994;20(1):112–6.

    Article  CAS  PubMed  Google Scholar 

  78. Eckstein RP, Dowsett JF, Lunzer MR. Flucloxacillin induced liver disease: histopathological findings at biopsy and autopsy. Pathology. 1993;25(3):223–8.

    Article  CAS  PubMed  Google Scholar 

  79. Chitturi S, Farrell GC. Drug-induced cholestasis. Semin Gastrointest Dis. 2001;12(2):113–24.

    CAS  PubMed  Google Scholar 

  80. Ishii M, Miyazaki Y, Yamamoto T, Miura M, Ueno Y, Takahashi T, et al. A case of drug-induced ductopenia resulting in fatal biliary cirrhosis. Liver. 1993;13(4):227–31.

    Article  CAS  PubMed  Google Scholar 

  81. He K, Cai L, Shi Q, Liu H, Woolf TF. Inhibition of MDR3 activity in human hepatocytes by drugs associated with liver injury. Chem Res Toxicol. 2015;28(10):1987–90.

    Article  CAS  PubMed  Google Scholar 

  82. Alam I, Ferrell LD, Bass NM. Vanishing bile duct syndrome temporally associated with ibuprofen use. Am J Gastroenterol. 1996;91(8):1626–30.

    CAS  PubMed  Google Scholar 

  83. Basturk A, Artan R, Yılmaz A, Gelen MT, Duman O. Acute vanishing bile duct syndrome after the use of ibuprofen. Arab J Gastroenterol. 2016;17(3):137–9.

    Article  PubMed  Google Scholar 

  84. Kim H, Yang HK, Kim SH, Park JH. Ibuprofen associated acute vanishing bile duct syndrome and toxic epidermal necrolysis in an infant. Yonsei Med J. 2014;55(3):834–7.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Xie W, Wang Q, Gao Y, Pan CQ. Vanishing bile duct syndrome with hyperlipidemia after ibuprofen therapy in an adult patient: a case report. BMC Gastroenterol. 2018;18(1):142.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Imipramine. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK547884/. Accessed 27 Apr 2020.

  87. Macrolide Antibiotics. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548398/. Accessed 27 Apr 2020.

  88. Schumaker AL, Okulicz JF. Meropenem-induced vanishing bile duct syndrome. Pharmacotherapy. 2010;30(9):953.

    Article  PubMed  Google Scholar 

  89. Phenytoin. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548889/. Accessed 27 Apr 2020.

  90. Lok AS, Ng IO. Prochlorperazine-induced chronic cholestasis. J Hepatol. 1988;6(3):369–73.

    Article  CAS  PubMed  Google Scholar 

  91. Prochlorperazine. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548122/. Accessed 27 Apr 2020.

  92. Orman ES, Conjeevaram HS, Vuppalanchi R, Freston JW, Rochon J, Kleiner DE, et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol. 2011;9(6):517–523.e3.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  93. Moxifloxacin. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548166/. Accessed 27 Apr 2020.

  94. Robinson W, Habr F, Manlolo J, Bhattacharya B. Moxifloxacin associated vanishing bile duct syndrome. J Clin Gastroenterol. 2010;44(1):72–3.

    Article  PubMed  Google Scholar 

  95. Mallat A, Zafrani ES, Metreau JM, Dhumeaux D. Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts. Dig Dis Sci. 1997;42(7):1486–8.

    Article  CAS  PubMed  Google Scholar 

  96. van ‘tWout JW, Herrmann WA, de Vries RA, Stricker BH. Terbinafine-associated hepatic injury. J Hepatol. 1994;21(1):115–7.

    Article  Google Scholar 

  97. Terbinafine. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548617/. Accessed 27 Apr 2020.

  98. Farrell GC. Drug-induced hepatic injury. J Gastroenterol Hepatol. 1997;12(9–10):S242–50.

    Article  CAS  PubMed  Google Scholar 

  99. Doxycycline. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548353/. Accessed 27 Apr 2020.

  100. Roy MA, Nugent FW, Aretz HT. Micronodular cirrhosis after thiabendazole. Dig Dis Sci. 1989;34(6):938–41.

    Article  CAS  PubMed  Google Scholar 

  101. Trifluoperazine. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548927/. Accessed 27 Apr 2020.

  102. Erlinger S. Drug-induced cholestasis. J Hepatol. 1997;26(Suppl 1):1–4.

    Article  CAS  PubMed  Google Scholar 

  103. Faria LC, Resende CC, Couto CA, Couto OFM, Fonseca LPC, Ferrari TCA. Severe and prolonged cholestasis caused by trimethoprim-sulfamethoxazole: a case report. Clinics (Sao Paulo). 2009;64(1):71–4.

    Article  Google Scholar 

  104. Kowdley KV, Keeffe EB, Fawaz KA. Prolonged cholestasis due to trimethoprim sulfamethoxazole. Gastroenterology. 1992;102(6):2148–50.

    Article  CAS  PubMed  Google Scholar 

  105. Vuppalanchi R, Chalasani N, Saxena R. Restoration of bile ducts in drug-induced vanishing bile duct syndrome due to zonisamide. Am J Surg Pathol. 2006;30(12):1619–23.

    Article  PubMed  Google Scholar 

  106. Horsley-Silva JL, Dow EN, Menias CO, Smith ML, Carballido EM, Lindor KD, et al. Docetaxel induced sclerosing cholangitis. Dig Dis Sci. 2015;60(12):3814–6.

    Article  PubMed  Google Scholar 

  107. Floxuridine. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http://www.ncbi.nlm.nih.gov/books/NBK548421/. Accessed 27 Apr 2020.

  108. Ludwig J, Kim CH, Wiesner RH, Krom RA. Floxuridine-induced sclerosing cholangitis: an ischemic cholangiopathy? Hepatology. 1989;9(2):215–8.

    Article  CAS  PubMed  Google Scholar 

  109. Schwab GP, Wetscher GJ, Vogl W, Redmond E. Methimazole-induced cholestatic liver injury, mimicking sclerosing cholangitis. Langenbecks Arch Chir. 1996;381(4):225–7.

    Article  CAS  PubMed  Google Scholar 

  110. Matsumoto S, Watanabe K, Kobayashi N, Irie K, Yamanaka S, Kaneko T. Pembrolizumab-induced secondary sclerosing cholangitis in a non-small cell lung cancer patient. Respirol Case Rep. 2020;8(5):e00560.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Karnsakul W, Arkachaisri T, Atisook K, Wisuthsarewong W, Sattawatthamrong Y, Aanpreung P. Vanishing bile duct syndrome in a child with toxic epidermal necrolysis: an interplay of unbalanced immune regulatory mechanisms. Ann Hepatol. 2006;5(2):116–9.

    Article  PubMed  Google Scholar 

  112. Olsson R, Wiholm BE, Sand C, Zettergren L, Hultcrantz R, Myrhed M. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol. 1992;15(1–2):154–61.

    Article  CAS  PubMed  Google Scholar 

  113. Pichler WJ. The p-i concept: pharmacological interaction of drugs with immune receptors. World Allergy Organ J. 2008;1(6):96–102.

    Article  PubMed  PubMed Central  Google Scholar 

  114. Barbatis C, Woods J, Morton JA, Fleming KA, McMichael A, McGee JO. Immunohistochemical analysis of HLA (A, B, C) antigens in liver disease using a monoclonal antibody. Gut. 1981;22(12):985–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Feng J, Li M, Gu W, Tang H, Yu S. The aberrant expression of HLA-DR in intrahepatic bile ducts in patients with biliary atresia: an immunohistochemistry and immune electron microscopy study. J Pediatr Surg. 2004;39(11):1658–62.

    Article  PubMed  Google Scholar 

  116. Demetris AJ, Lasky S, Van Thiel DH, Starzl TE, Whiteside T. Induction of DR/IA antigens in human liver allografts. An immunocytochemical and clinicopathologic analysis of twenty failed grafts. Transplantation. 1985;40(5):504–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Ogese MO, Ahmed S, Alferivic A, Betts CJ, Dickinson A, Faulkner L, et al. New approaches to investigate drug-induced hypersensitivity. Chem Res Toxicol. 2017;30(1):239–59.

    Article  CAS  PubMed  Google Scholar 

  118. Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, et al. Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study. Gastroenterology. 2017;152(5):1078–89.

    Article  CAS  PubMed  Google Scholar 

  119. Liu Z-X, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis. 2002;6(3):755–74.

    Article  PubMed  Google Scholar 

  120. Trauner M, Arrese M, Lee H, Boyer JL, Karpen SJ. Endotoxin downregulates rat hepatic ntcp gene expression via decreased activity of critical transcription factors. J Clin Invest. 1998;101(10):2092–100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Fardel O, Le Vée M. Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines. Expert Opin Drug Metab Toxicol. 2009;5(12):1469–81.

    Article  CAS  PubMed  Google Scholar 

  122. Pirmohamed M, Naisbitt DJ, Gordon F, Park BK. The danger hypothesis--potential role in idiosyncratic drug reactions. Toxicology. 2002;181–182:55–63.

    Article  PubMed  Google Scholar 

  123. Ali AH, Tabibian JH, Lindor KD. Update on pharmacotherapies for cholestatic liver disease. Hepatol Commun. 2017;1(1):7–17.

    Article  PubMed  Google Scholar 

  124. European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237–67.

    Article  Google Scholar 

  125. Bakhit M, McCarty TR, Park S, Njei B, Cho M, Karagozian R, et al. Vanishing bile duct syndrome in Hodgkin’s lymphoma: a single center experience and clinical pearls. J Clin Gastroenterol. 2016;50(8):688.

    Article  PubMed  PubMed Central  Google Scholar 

  126. Brooling J, Leal R. Secondary sclerosing cholangitis: a review of recent literature. Curr Gastroenterol Rep. 2017;19(9):1–7.

    Article  Google Scholar 

  127. Cwikiel M, Zhang B, Eskilsson J, Wieslander JB, Albertsson M. The influence of 5-fluorouracil on the endothelium in small arteries. An electron microscopic study in rabbits. Scanning Microsc. 1995;9(2):561–76.

    CAS  PubMed  Google Scholar 

  128. Spasojević I, Jelić S, Zakrzewska J, Bačić G. Decreased oxygen transfer capacity of erythrocytes as a cause of 5-fluorouracil related ischemia. Molecules. 2008;14(1):53–67.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy

    Sara De Martin & Daniela Gabbia

  2. Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy

    Emanuela Bonaiuto

Authors
  1. Sara De Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emanuela Bonaiuto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniela Gabbia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sara De Martin .

Editor information

Editors and Affiliations

  1. Scientific Consultant, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) Negrar, Verona, Italy

    Annarosa Floreani

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

De Martin, S., Bonaiuto, E., Gabbia, D. (2021). Drug-Induced Cholangiopathies. In: Floreani, A. (eds) Diseases of the Liver and Biliary Tree. Springer, Cham. https://doi.org/10.1007/978-3-030-65908-0_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-65908-0_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-65907-3

  • Online ISBN: 978-3-030-65908-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation